CPA
RVNC

Capital Performance Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Capital Performance Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-412
Closed -$2.14K – 2861
2024
Q3 		$2.14K Buy
+412
New +$2.05K ﹤0.01% 1525

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Capital Performance Advisors's RVNC Position: Q4 2024 in Review

Capital Performance Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 412 shares — an estimated $2.14K sold.

Capital Performance Advisors first reported a position in RVNC in Q3 2024 and held it in 1 quarter. The position peaked at $2.14K in Q3 2024. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Capital Performance Advisors reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 412 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $2.14K.
  • Capital Performance Advisors first reported a position in Revance Therapeutics, Inc. in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Revance Therapeutics, Inc. position peaked at $2.14K in Q3 2024.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.